Efficacy and Safety Study of SUNPG1622

Inclusion Criteria: * Subject has provided informed written consent * Subject is ≥ 18 years of age at time of Screening * Subject must be on a stable dose of NSAID for ≥ 2 weeks prior to initiation of investigational product * Subject has a negative test for TB within 4 weeks before initiating IMP Exclusion Criteria: * Subjects with known diagnosis of fibromyalgia or complex regional pain syndromes * Active uveitis or symptomatic inflammatory bowel disease requiring therapy at screening * Radiographic evidence of total ankylosis of the spine * Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pre-treatment condition